Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended December 31, 2023. The company is a clinical-stage biopharmaceutical developer with no approved products or product-sales revenue. Financial statements are unaudited.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2023 | Nine months ended Dec. 31, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | $0.41 million | $0.87 million | $0.18 million; $(0.40) million, respectively |
| Research and development | $4.54 million | $12.59 million | $6.85 million; $35.04 million, respectively |
| General and administrative | $3.76 million | $9.94 million | $3.09 million; $11.59 million, respectively |
| Net loss | $6.35 million | $19.84 million | $9.76 million; $47.02 million, respectively |
| Net loss per share | $0.22 | $1.27 | $1.42; $6.82, respectively |
- Revenue is primarily sublicense and other revenue, not product sales. The 2022 nine-month comparison includes a $892,500 cumulative revenue reversal under the AffaMed agreement; this explains the negative reported revenue.
- For the nine-month period, operating cash use was $18.62 million, versus $42.24 million in 2022. Investing cash use was $0.03 million. Financing provided $128.57 million, principally from equity offerings and the Fuji Pharma payment. Cash increased $109.92 million to $126.56 million.
- At December 31, 2023, current assets were $128.11 million and current liabilities were $4.16 million. Total liabilities were $7.78 million; the company reported no note payable at quarter-end. Lease obligations totaled approximately $2.25 million.
- Accumulated deficit was $346.69 million. Management said cash on hand was expected to fund operating expenses and capital needs for more than 12 months from issuance of the statements. The prior fiscal-year auditor’s report had raised substantial doubt about the company’s ability to continue as a going concern.
- No product gross margin is presented; the filing reports no product sales and does not provide a meaningful product-margin measure.
Material changes and financing
- Nine-month R&D expense fell by $22.45 million year over year, mainly because of the timing of costs and closeout expenses for the PALISADE-1 and PALISADE-2 fasedienol trials. Management expects R&D spending to rise substantially as development advances.
- Quarterly G&A expense increased year over year, largely due to compensation costs. Nine-month G&A declined, primarily from lower stock-based compensation and consulting fees.
- The October 2023 public offering generated approximately $93.5 million net proceeds. It included common shares and pre-funded warrants, together with T1 and T2 warrants. The company also received $36.2 million net from sales under its at-the-market agreement during the nine months.
- Common shares issued increased from 7.32 million at March 31, 2023 to 27.03 million at December 31, 2023. In addition, 20.60 million common-stock warrants were outstanding at quarter-end, creating potential dilution if exercised.
- Fuji Pharma paid $1.5 million for an exclusive negotiation period concerning a potential PH80 license in Japan. Neither party is obligated to enter a definitive license agreement; the payment may be credited against a future upfront fee.
Pipeline, outlook, and principal risks
- Fasedienol: PALISADE-2 Phase 3 met its primary endpoint and reported positive secondary and exploratory results. PALISADE-1 did not meet its primary endpoint. Management planned PALISADE-3 for the first half of 2024 and PALISADE-4 for the second half of 2024, plus a repeat-dose study in the second half of 2024. The filing describes these as plans, not completed milestones.
- Other candidates: The company was preparing for potential Phase 2B development of itruvone for major depressive disorder and nonclinical work for PH80, with U.S. development under consideration. It was assessing next steps for PH15, PH284, and AV-101.
- Management expects operating losses and negative operating cash flows to continue and anticipates higher research, development, manufacturing, regulatory, and public-company costs. It may need additional financing; future funding may be unavailable or dilutive or require unfavorable terms.
- Key risks include clinical-trial failure or delay (including uncertainty following the different PALISADE-1 and PALISADE-2 outcomes), regulatory approval and commercialization uncertainty, reliance on third-party manufacturers and trial operators, competition, intellectual-property challenges, and potential effects of olfactory dysfunction on pherine nasal-spray efficacy.
- The filing reports no legal proceedings. Management concluded disclosure controls were effective as of December 31, 2023, and reported no material quarterly change in internal control over financial reporting.
Investor facts to verify
- Progress, timing, design, and results of PALISADE-3 and PALISADE-4, and how regulators view the mixed PALISADE-1 and positive PALISADE-2 results.
- Cash burn against the stated runway, upcoming trial and manufacturing costs, and whether additional financing or partnering is needed.
- Potential dilution from outstanding pre-funded warrants, T1/T2 warrants, and any future equity sales.
- Whether the Fuji Pharma negotiations result in a definitive PH80 license and what financial terms, if any, follow.
- Whether the planned studies for itruvone, PH80, and other candidates proceed on schedule and produce results that support further development.